Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;12(3):289-299.
doi: 10.1007/s11523-017-0489-2.

Cancer Immunotherapy with Cytokine-Induced Killer Cells

Juan J Mata-Molanes  1 , Manuel Sureda González  2 , Belén Valenzuela Jiménez  2 , Elena Mª Martínez Navarro  2 , Antonio Brugarolas Masllorens  2
Affiliations
Review

Cancer Immunotherapy with Cytokine-Induced Killer Cells

Juan J Mata-Molanes et al. Target Oncol. 2017 Jun.

Abstract

Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+). The ready availability of a lymphocyte source, together with the high proliferative rate and potent anti-tumor activity of CIK cells, has allowed their use as immunotherapy in a wide variety of neoplasms. Cytotoxicity mediated by CD3+CD56+ T cells depends on the major histocompatibility antigen (MHC)-independent recognition of tumor cells and the activation of signaling pathways through the natural killer group 2 member D (NKG2D) cell-surface receptor. Clinical trials have demonstrated the feasibility and efficacy of CIK cell immunotherapy even in advanced stage cancer patients or those that have not responded to first-line treatment. This review summarizes biological and technical aspects of CIK cells, as well as past and current clinical trials and future trends in this form of immunotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Immunother. 2014 Jan;37(1):43-50 - PubMed
    1. Br J Cancer. 1999 Nov;81(6):1009-16 - PubMed
    1. Chin Med J (Engl). 2012 Nov;125(21):3771-7 - PubMed
    1. Exp Ther Med. 2013 Oct;6(4):953-956 - PubMed
    1. Int J Hematol. 2014 Apr;99(4):361-71 - PubMed

MeSH terms

LinkOut - more resources